Proxalutamide

Kintor Pharma Announces 2021 Interim Results

Retrieved on: 
Monday, August 30, 2021
ACE2, GEJ, NFE2L2, PD-1, Protein, Welfare, Pattern hair loss, HCC, Research, Food, Exocrine gland, Brazilian Health Regulatory Agency, Hair loss, Safety, Partnership, GC, Woman, ANVISA, ASCO, Acne, Man, Squamous cell carcinoma, Clinical trial, Ministry, Pfizer, AGA, CEO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Reproduction, COVID-19, CDE, II, Coronavirus, Patient, Alpha, EUA, Nivolumab, UC, III, FDA, TMPRSS2, Hair follicle, HKEX, Proxalutamide, Infection, AR, PROTAC, ESCC, Inflammation, IND, Stomach, Public health, Gamma, Pharmaceutical industry, Medical imaging, Generic drug

SUZHOU, CHINA, Aug 30, 2021 - (ACN Newswire) - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities in Hong Kong capital market.

Key Points: 
  • SUZHOU, CHINA, Aug 30, 2021 - (ACN Newswire) - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities in Hong Kong capital market.
  • Dr.Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented,
    "In the first half of 2021, Kintor Pharma has made great progress in areas including research, clinical operations, and business cooperation with reputable partners.
  • In 2021, Kintor Pharma received greenlight from the U.S. Food and Drug Administration (FDA) and the approval from Brazilian Health Regulatory Agency (ANVISA) to conduct phase III clinical trials with proxalutamide in patients with COVID-19.
  • Meanwhile, Kintor Pharma is working on designing clinical trials for combination therapy of ALK-1/VEGF dual-targeting antibody for solid tumor types.

Kintor Pharma Collaborates with Etana to Commercialize Proxalutamide for Treatment of COVID-19 in Indonesia

Retrieved on: 
Wednesday, August 25, 2021
Union, ACE2, COVID-19, Proxalutamide, European Union, Prostate, AR, Acne, EPO, Patient, Hair, Anemia, EUA, Chronic kidney disease, End-user license agreement, Safety, CEO, Breast, III, TMPRSS2, Pharmaceutical industry

Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, "We are excited to establish a strategic collaboration with Etana.

Key Points: 
  • Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, "We are excited to establish a strategic collaboration with Etana.
  • Recently, the highly contagious Delta strain of COVID-19 variant has been reported in many countries around the world,including Indonesia.
  • In collaboration with Etana, we believe that proxalutamide will serve as an important tool in the fight against COVID-19 pandemic in Indonesia."
  • Proxalutamide is a new-generation androgen receptor (AR) antagonist regulates the expression of TMPRSS2 and ACE2 developed by Kintor Pharma.

Kintor Pharmaceutical Collaborates with Fosun Pharma Development to Commercialise Proxalutamide for Treatment of COVID-19 in India and Africa

Retrieved on: 
Thursday, July 15, 2021
Companies of China, Companies, Economy of China, Fosun International, H shares, Fosun Pharma, Sun Pharma, Guo Guangchang

Kintor and Fosun Pharma Development will collaborate on the emergency use authorization applications, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.

Key Points: 
  • Kintor and Fosun Pharma Development will collaborate on the emergency use authorization applications, promotion, and sales of proxalutamide for the treatment of COVID-19 indication.
  • According to the licensing agreement, Fosun Pharma Development will be granted exclusive rights of registration and commercialisation of proxalutamide in the Collaboration Regions.
  • Shanghai Fosun Pharmaceutical Development Ltd. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma Group";stock code: 600196.SH, 02196.HK) is a leading global pharmaceutical and healthcare provider in China.

Kintor Pharmaceutical and Visum Announced Strategic Partnership to Expand Proxalutamide Manufacturing

Retrieved on: 
Wednesday, April 14, 2021
Chemical compounds, Health sciences, Organic compounds, Pharmaceutical industry, Pharmacology, Pharmacy, Proxalutamide

b'SUZHOU, China, April 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics,recently announced a strategic partnership with Hainan Visum Pharmaceutical Limited ("Visum") to expand proxalutamide manufacturing.\nAt present, Kintor Pharmaceuticalis completing the Brazilian clinical trials of proxalutamidefor treatment of male and female COVID-19 patients with mild or moderate symptoms and COVID-19 patients with severe symptoms.

Key Points: 
  • b'SUZHOU, China, April 14, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics,recently announced a strategic partnership with Hainan Visum Pharmaceutical Limited ("Visum") to expand proxalutamide manufacturing.\nAt present, Kintor Pharmaceuticalis completing the Brazilian clinical trials of proxalutamidefor treatment of male and female COVID-19 patients with mild or moderate symptoms and COVID-19 patients with severe symptoms.
  • Youzhi Tong, co-founder, chairman, and CEO of Kintor Pharmaceutical, said, "We are pleased to partner with Visum.
  • With the clinical progress Kintor is making with proxalutamide for COVID-19 indications, Kintor needs to rapidly expand its existing GMP production capacity to cope with the demand necessary to fight the epidemic.
  • Zhu Honggang, chairman of Visum, said, "It is a great honor to be able to provide high-quality and high-efficiency manufacturing services for Kintor as they approach regulatory approvals for proxalutamide.